About Us
RR MedSciences is dedicated to driving change and transforming lives by forging a new path in the treatment of pain and inflammatory conditions
Founded in 2014, RR MedSciences is a clinical-stage biopharmaceutical company responsible for the patented small-molecule complex RM191A.
This novel complex is the foundation for RR MedSciences platform technology and product pipeline.
We are focused on the development of novel analgesics for the treatment of neuropathic, inflammatory and skeletal pain, and the development of therapeutics for the treatment of inflammatory driven conditions.
RR MedSciences directs extensive pre-clinical research and clinical trials in collaboration with research teams at the Australian Centre for Nanomedicine, the ARC Centre of Excellence in Convergent Bio-Nano Science, the Kolling Institute for Medical Research, Sydney University, University of NSW, and Macquarie University.
Our Team
Our team is highly accomplished with decades of clinical, medical and entrepreneurial business and product development expertise. We are specialists in formulation chemistry, biomed drug and product development with a particular focus on pain and inflammatory-related diseases.
Our collaborators are specialist researchers and clinicians in the fields of chemistry and physiology, biomolecular science, biology, neurology, neuroscience, pain, and clinical oncology.
Llewellyn Casbolt
Board Chair, Chief Scientific Officer
Llewellyn has an extensive career in corporate management and in biochem medical research and product development. With MD or CEO roles, Llewellyn has led drug and product development at multiple Australian biomed companies, including an ASX listed biotech, a biotech incubator, an international veterinary pharmaceutical, and an Australian medical device company prior to RR MedSciences.
Llewellyn’s research career spans more than thirty years. After a BAppSc Chemistry at Monash University he was recruited to an elite global development team at Nicholas (Kiwi) International, with positions in Australia, the UK and USA. After a time in corporate management in the financial sector, he returned to his love of med-tech.
Llewellyn has a specialty in the development of metallo-complexes, anti-inflammatory drugs and novel formulation expertise. He is responsible for RR MedSciences' core drug discovery and its research collaborations. Llewellyn is cited on the Redox Biology Jan 2021 Journal overview of the multiple studies of the RM191A compound on the skin.
Sofia Casbolt
Chief Executive Officer
Sofia is a leader with a background in science, anthropology, and communications. She is fascinated by the intersection of these disciplines and how they can be utilised to develop new approaches to future health. She is passionate about driving transformative change in the health sector, particularly in the treatment of pain and inflammatory conditions, and has previous experience in the oncology sector.
With over a decade’s experience in management and program development, her expertise lies in identifying and executing strategic opportunities that align with long-term objectives, ensuring sustainable growth and innovation. She enjoys fostering strong partnerships and navigating complex operational challenges to deliver impactful results.
Sofia is now driving strategic development, R&D, and product commercialisation to deliver therapeutics to market for RR MedSciences and make a meaningful difference to the lives of people living with inflammation and pain.
Sofia has a Bachelor of Science in Chemistry, and a Bachelor of Arts in Anthropology from Macquarie University. She has completed courses at Harvard Business School and Cicada Innovations.
Advisory Board
RR MedSciences' Advisors are leaders in their fields and bring independent views to our development based on their expertise.
Kenneth B. Clark
Partner Emeritus, Fenwick & West LLP
Former Chair, Tax Controversy Group, Fenwick & West LLP
With over four decades of practice at Fenwick, Kenneth has advised numerous large and small companies in a variety of fields. He has provided legal and strategic advice on start up matters, litigation issues, and real estate problems. He has helped resolve business and legal problems in numerous countries, spanning Europe, Asia, Australia and North America.
Kenneth is now a partner emeritus of Fenwick. He led Fenwick & West’s award-winning tax controversy practice since its formation, working on high-profile tax controversy matters in the United States and internationally. Kenneth’s group and Fenwick’s tax practice have represented 50 of the Fortune 100 companies of the world. Fenwick has received numerous accolades for its tax controversy practice, including recognition by International Tax Review as the top controversy practice in North America and as the U.S. tax litigation firm of the year in a number of different years.
Kenneth has worked on important matters for such companies as Apple Computer, CBS, Xilinx, Victoria’s Secret, Limited Brands, Chrysler AG, Cameco Corporation, and VF Corporation. He has been included in International Tax Review’s World’s Controversy Leaders and Euromoney’s World’s Leading Transfer Pricing Advisors, among other accolades.
Educational Background:
Kenneth received a B.A. from the University of Redlands, where he graduated first in his class. He received a J.D. from New York University School of Law, with honors, and was a member of that school's Law Review. Kenneth also received an M.B.A. from the University of California at Berkeley. He has extensive experience in teaching speaking techniques and won the U.S. freshman national collegiate debate championship.